Repeat cadaver kidney transplantation using cyclosporine A immunosuppression

Area of Science:

• Nephrology
• Transplantation Immunology
• Immunosuppression Therapy

Background:

• Repeat kidney transplantation is associated with higher graft loss compared to primary transplants.
• Azathioprine immunosuppression in repeat transplants demonstrated a significant risk of graft failure.
• Cyclosporine A emerged as a potential alternative for improving outcomes in repeat cadaver kidney transplantation.

Purpose of the Study:

• To evaluate the efficacy of cyclosporine A in repeat cadaver kidney transplantation.
• To compare graft survival rates between cyclosporine A-treated and azathioprine-treated second graft recipients.
• To identify factors influencing the outcome of repeat kidney transplants.

Main Methods:

• Retrospective analysis of 33 patients undergoing repeat cadaver kidney transplantation with cyclosporine A.
• Comparison with a concurrent group of 189 first-time cadaver kidney recipients treated with cyclosporine A.
• Comparison with a historical group of 31 second graft recipients treated with azathioprine.

Main Results:

• One-year graft survival for cyclosporine A-treated repeat transplants was 66%.
• Cyclosporine A-treated first transplants had a 1-year graft survival of 75% (not statistically significant difference).
• Azathioprine-treated second grafts showed a significantly lower 1-year survival rate of 45% compared to cyclosporine A.
• Patient demographics and immunological factors (except DR mismatch) did not predict second graft outcome.

Conclusions:

• Cyclosporine A offers acceptable early graft survival for repeat cadaver kidney transplants.
• Cyclosporine A demonstrates superior outcomes compared to azathioprine for second kidney grafts.
• A complete DR mismatch may negatively impact second transplant survival, warranting further investigation.